The effect of indacaterol during an acute exacerbation of COPD

详细信息    查看全文

• 作者：Andrea Segreti ; Enrica Fiori ; Luigino Calzetta ; Marco Sabatini ; Vincenzo Segreti ; Paola Rogliani ; Mario Cazzola
• 关键词：COPD ; Exacerbation ; Indacaterol ; Salbutamol
• 刊名：Pulmonary Pharmacology & Therapeutics
• 出版年：December, 2013
• 年：2013
• 卷：26
• 期：6
• 页码：630-634
• 全文大小：449 K

文摘

Some clinical trials have suggested that the inhaled long-acting 尾₂-agonists (LABAs) may be effective in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since indacaterol, the first once-daily LABA to be developed for the regular treatment of COPD, exhibits fast onset of action and 24-h duration of bronchodilation, we have investigated its effects in patients with AECOPD managed in the emergency department.

In a randomised controlled pilot trial, we have enrolled 29 consecutive patients with a recent (i.e.,聽within 鈮?聽d) history of AECOPD and requiring hospitalization. All patients received a standard protocol consisting of ipratropium bromide aerosol 500聽渭g three times a day, intravenous methylprednisolone 20聽mg twice-daily and, if indicated, oral levofloxacin 500聽mg once-daily. Moreover, they were randomly allocated to one of the two 5-day treatment groups (indacaterol maleate 300聽渭g once-daily or salbutamol nebulizer 1250聽渭g three times a day).

The administration of indacaterol 300聽渭g to patients admitted to emergency department for an AECOPD resulted in a greater improvement of pulmonary function compared with traditional therapy, without cardiovascular side effects.

Our results suggest that indacaterol could be a useful option in the treatment of AECOPD. However, further larger double-blinded randomized clinical trials are needed to validate the intriguing results obtained in this setting.